News Category
In vitro ADME studies are critical for early evaluation of drug candidates, helping to avoid costly late-stage failures and accelerate the drug develo...
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal Clade I mpox and other orthopoxviruses, potentially ...
Onco-Innovations is advancing its lead preclinical cancer candidate ONC010 toward first-in-human testing by aligning manufacturing, formulation, and r...
VERAXA Biotech has named Raju Willener as its new chief financial officer, bringing over 30 years of international capital markets experience to help ...
Apimeds Pharmaceuticals US (NYSE American: APUS) has hired IBN to handle its corporate communications, aiming to raise investor awareness for its subs...
Regentis Biomaterials CEO Dr. Ehud Geller discussed the company's lead product GelrinC, its U.S. pivotal trial and European commercialization, emphasi...
Silo Pharma receives a U.S. patent Notice of Allowance for its intranasal PTSD treatment SPC-15, strengthening its intellectual property portfolio and...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, addressing a significant unmet ne...
Med-X is expanding its Nature-Cide natural pest-control brand and has obtained OMRI certification for key products, positioning itself for growth as i...
Telomir Pharmaceuticals reports that its lead candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines, supporting further tr...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial aims to provide independent validation and suppor...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities, offering customized targeted and stimuli-respon...
Creative Biolabs has upgraded its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processin...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering new av...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, highlighting...
Regentis Biomaterials reported a narrowed net loss for the first half of 2026 and progress in its pivotal Phase III trial for GelrinC, a potential fir...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, has received FDA clearance for a Phase 2 trial, potentially offering a new trea...
TransCode Therapeutics' CFO retirement and appointment of an interim successor could affect financial oversight as the company advances its cancer the...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager technolo...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially offering a novel approach that tar...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective therapy, has received FDA clearance for a Phase 2 trial, potentially transforming the...
Quantum BioPharma's Lucid-MS, the first drug designed to protect and rebuild myelin, receives FDA clearance for a phase 2 trial, potentially transform...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, highlighting the company's late-stage clini...
Onco-Innovations' CMO discusses the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP with a dual selectivity approach, a...
Quantum BioPharma's FDA clearance for its Lucid-MS Investigational New Drug application marks a pivotal step toward a Phase 2 trial, potentially offer...
American Fusion Inc. has transitioned its Texatron fusion program from prototype development to active testing, achieving peak pressures of 100,000 at...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's progress in developing ENV-105, a promising therapy aimed ...
Nutriband's CEO participation in the Nasdaq LaB Biotech Summit highlights the company's strategic engagement with investors and industry leaders, pote...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its progress in developing SPC-15, a nose-to-brain drug delivery sy...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel myelin-repair approach in multiple sclerosis, d...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its multiple sclerosis drug Lucid-MS has garnered a new buy rating and media spotlight, highl...
Helus Pharma's CEO participation at a major investment conference underscores the company's progress in developing novel serotonergic agonists for men...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to diversify supply and enhance preparedness.
Voyageur Pharmaceuticals has achieved a key milestone in its iodine production feasibility study, securing a $1 million payment from Bayer and advanci...
Greenland Mines announces a Q4 2026 spin-off of its biotech division and key milestones in its transition to a critical minerals company, including Na...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to bolster its financial leadership and advance its proprietary BiTAC te...
Scinai Immunotherapeutics refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its license with PinCell, aiming to p...
Onco-Innovations Ltd. strengthens its clinical foundation through manufacturing milestones, IND-enabling activities, and funding, positioning its PNKP...
OS Animal Health, a subsidiary of OS Therapies, is spotlighted at the Moody Capital conference for its promising OST-HER2 immunotherapy targeting cani...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a potential breakthrough in treatin...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a phase 2 trial could herald a new era in MS therapy, add...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Greenland Mines' plan to spin off its biotech division and its completed acquisition of the Sarfartoq rare earths project underscore its strategic piv...
Quantum BioPharma gains FDA clearance to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, marking a significant step for a first-in-class ther...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial could revolutionize MS therapy by targeting demyelination rather than immunosuppression, ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination, could redefine MS therapy by offerin...
